The role of the gut lymphoid tissue in induction of oral tolerance

Current Opinion in Investigational Drugs

Volumn 2, Issue 10, 2001, Pages 1382-1386

  Song, F ^a   Whitacre, C C ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Gut associated lymphoid tissue; Oral tolerance; Peyer's patch; T lymphocyte

Indexed keywords

ANTIGEN; CHOLERA TOXIN B SUBUNIT; COLLAGEN; GLATIRAMER; GROWTH FACTOR; MYELIN BASIC PROTEIN; OVALBUMIN; PLACEBO; RECOMBINANT HUMAN INSULIN;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; CLONAL ANERGY; DIABETES MELLITUS; DISEASE MODEL; DRUG POTENTIATION; EXPERIMENTAL ANIMAL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; INTESTINE; LYMPHOID TISSUE; MICROORGANISM; NONHUMAN; PEYER PATCH; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; DIETARY PROTEINS; DIGESTIVE SYSTEM; FOOD HYPERSENSITIVITY; HUMANS; LYMPHOID TISSUE; MODELS, BIOLOGICAL;

EID: 0034777321     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Overview of the mucosal immune system
2. Phenotypes of T cells in the gut
3. Immunologic effects of encapsulated short ragweed extract: A potent new agent for oral immunotherapy
4. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein
5. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy
6. Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein
7. 139-151 peptide
8. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes
9. Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen
10. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen
11. Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen
12. Suppression of experimental autoimmune uveitis in rats by the oral administration of the uveitopathogenic S-antigen fragment or a cross-reactive homologous peptide
13. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): Induction of protective tolerance in primed animals
14. Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity
15. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin
16. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes
17. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes
18. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis
19. Oral type II collagen treatment in early rheumatoid arthritis: A double-blind placebo-controlled, randomized trial
20. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis
21. Effects of oral administration of type II collagen on rheumatoid arthritis
22. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
23. Direct measurement of anergy of antigen-specific T cells following oral tolerance induction
24. Oral tolerance in experimental autoimmune encephalomyelitis
25. The role of clonal deletion and anergy in oral tolerance
26. Inactivation of Th1 and Th2 cells by feeding ovalbumin
27. A cell culture model for T lymphocyte clonal anergy
28. Peripheral deletion of antigen-reactive T cells in oral tolerance
29. T-cell activation and receptor downmodulation precede deletion induced by mucosally administered antigen
30. Putative role of p55 TNF receptor, but not Fas, in oral tolerance
31. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis
32. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
33. Regulatory T cells and inflammatory bowel disease
34. + T cells: A population of T cells with immune regulatory activities in vitro
35. Oral tolerance: Mechanisms and therapeutic applications
36. T cell immunity to oral allergens
37. Oral tolerance in disease
38. Normal induction of oral tolerance in the absence of a functional IL-12-dependent IFN-gamma signaling pathway
39. T helper 2 cells are subject to high dose oral tolerance and are not essential for its induction
40. IL-4 and IL-10 are both required for the induction of oral tolerance
41. Induction of oral tolerance in TGF-beta 1 null mice
42. Anti-IL-10 treatment does not block either the induction or the maintenance of orally induced tolerance to OVA
43. Monocyte chemotactic protein 1 regulates oral tolerance induction by inhibition of T helper cell 1-related cytokines
44. Orally induced peripheral nonresponsiveness is maintained in the absence of functional Th1 or Th2 cells
45. Tracking and the fate of T cells during oral tolerance in experimental autoimmune encephalomyelitis (EAE)
46. Antigen-specific T cell activation and proliferation during oral tolerance induction
47. A bone marrow-derived APC in the gut-associated lymphoid tissue captures oral antigens and presents them to both CD4+ and CD8+ T cells
48. The role of dendritic cells, B cells, and M cells in gut-oriented immune responses
49. Expanding dendritic cells in vivo enhances the induction of oral tolerance
50. Enhancement of oral tolerance in experimental autoimmune encephalomyelitis by expansion of dendritic cells
51. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells
52. Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch
53. Mucosal immunity and inflammation. I. Mucosal dendritic cells: Their specialized role in initiating T cell responses
54. Rapid deletion of peripheral antigen-specific T cells in TCR transgenic mice following oral administration of myelin basic protein
55. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients
56. Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis
57. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial
58. Treatment of uveitis by oral administration of retinal antigens: Results of a phase I/II randomized masked trial
59. Molecular mimicry as a therapeutic approach for an autoimmune disease: Oral treatment of uveitis-patients with an MHC-peptide crossreactive with autoantigen - First results
60. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit
61. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity